ICD therapy: what have we learned from the clinical trials?
Development of implantable cardioverter defibrillators (ICD) has been a dramatic advancement in the management of patients with life-threatening ventricular arrhythmias. We hereby reviewed the landmark clinical trials on ICD with special emphasis on late-breaking clinical trials and assessed their impact on every-day decision making and patient selection for ICD implantation.
Arya
Arash
A
Department of Pacemaker and Electrophysiology, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Mellat Park, Vali-e-Asr Avenue, Tehran 1996911151, Iran. dr.arasharya@gmail.com
Haghjoo
Majid
M
Sadr-Ameli
Mohammad Ali
MA
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000628:therapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy / Q000379:methods; D016757:Death, Sudden, Cardiac / Q000209:etiology / Q000517:prevention & control*; D017147:Defibrillators, Implantable / Q000639:trends; D006333:Heart Failure / Q000628:therapy*; D006801:Humans; D017063:Outcome Assessment, Health Care; D010138:Pacemaker, Artificial; D013997:Time Factors; D016277:Ventricular Function, Left / Q000502:physiology
D000889:Anti-Arrhythmia Agents